Foghorn Therapeutics (FHTX) Accounts Payables (2020 - 2025)
Historic Accounts Payables for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $9.8 million.
- Foghorn Therapeutics' Accounts Payables fell 1245.21% to $9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 1245.21%. This contributed to the annual value of $8.5 million for FY2024, which is 633.51% down from last year.
- According to the latest figures from Q3 2025, Foghorn Therapeutics' Accounts Payables is $9.8 million, which was down 1245.21% from $8.6 million recorded in Q2 2025.
- In the past 5 years, Foghorn Therapeutics' Accounts Payables registered a high of $11.2 million during Q3 2024, and its lowest value of $2.9 million during Q1 2021.
- Its 5-year average for Accounts Payables is $8.0 million, with a median of $8.5 million in 2024.
- Its Accounts Payables has fluctuated over the past 5 years, first surged by 14081.07% in 2022, then crashed by 2905.67% in 2024.
- Quarter analysis of 5 years shows Foghorn Therapeutics' Accounts Payables stood at $9.6 million in 2021, then increased by 15.05% to $11.0 million in 2022, then fell by 17.21% to $9.1 million in 2023, then decreased by 6.34% to $8.5 million in 2024, then rose by 15.13% to $9.8 million in 2025.
- Its last three reported values are $9.8 million in Q3 2025, $8.6 million for Q2 2025, and $6.5 million during Q1 2025.